Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04826185 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
A Phase 2 study of Non-obstructive Hypertrophic Cardiomyopathy, sponsored by Imbria Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 14
- Study locations
NCT04826185 is a Phase 2 study of Non-obstructive Hypertrophic Cardiomyopathy that has completed, run by Imbria Pharmaceuticals. The registered enrollment target is 67 participants, below the 241-participant average among 3 other Non-obstructive Hypertrophic Cardiomyopathy trials with a reported enrollment target (72% lower). The trial reports 14 study locations across 11 states.
The verdict
NCT04826185, a Phase 2 study of Non-obstructive Hypertrophic Cardiomyopathy, has completed, sponsored by Imbria Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IMB-1018972
Study Locations (14)
California
- Imbria Investigational Site - La Jolla
- Imbria Investigational Site - Los Angeles
- Imbria Investigational Site - San Francisco
Massachusetts
- Imbria Investigational Site - Boston
- Imbria Investigational Site - Burlington
Illinois
- Imbria Investigational Site - Chicago
Missouri
- Imbria Investigational Site - St Louis
New Jersey
- Imbria Investigational Site - Morristown
New York
- Imbria Investigational Site - New York
North Carolina
- Imbria Investigational Site - Charlotte
Oregon
- Imbria Investigational Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2021-06-14 |
| Est. Completion | 2023-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04826185
The ClinicalTrials.gov registry entry for NCT04826185 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 3 other Non-obstructive Hypertrophic Cardiomyopathy trials with a reported enrollment target (72% lower). The listed sponsor is Imbria Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-obstructive Hypertrophic Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04826185 reports 14 study locations spanning 11 distinct geographic areas - top geographies include California, Massachusetts, Illinois.
Frequently Asked Questions
What is clinical trial NCT04826185 about?
NCT04826185 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial". The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.
What is the current status of trial NCT04826185?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2021-06-14. Estimated completion is 2023-09-18.
What conditions does trial NCT04826185 study?
This clinical trial studies the following conditions: Non-obstructive Hypertrophic Cardiomyopathy.
What interventions are being tested in trial NCT04826185?
The interventions under investigation include: Placebo (DRUG), IMB-1018972 (DRUG).
Who is sponsoring clinical trial NCT04826185?
This trial is sponsored by Imbria Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04826185 being conducted?
This trial has 14 study locations across California, Illinois, Massachusetts, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-obstructive Hypertrophic Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
RECRUITING · Phase 2
-
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.